JP2015536324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536324A5 JP2015536324A5 JP2015537790A JP2015537790A JP2015536324A5 JP 2015536324 A5 JP2015536324 A5 JP 2015536324A5 JP 2015537790 A JP2015537790 A JP 2015537790A JP 2015537790 A JP2015537790 A JP 2015537790A JP 2015536324 A5 JP2015536324 A5 JP 2015536324A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- pharmaceutical composition
- boron
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229910052796 boron Inorganic materials 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000005976 liver dysfunction Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- -1 cyclic borate ester Chemical class 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261714899P | 2012-10-17 | 2012-10-17 | |
| US61/714,899 | 2012-10-17 | ||
| PCT/US2013/065227 WO2014062794A1 (en) | 2012-10-17 | 2013-10-16 | Compositions and methods for improving glucose uptake |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536324A JP2015536324A (ja) | 2015-12-21 |
| JP2015536324A5 true JP2015536324A5 (https=) | 2016-12-01 |
| JP6377620B2 JP6377620B2 (ja) | 2018-08-22 |
Family
ID=49486728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537790A Active JP6377620B2 (ja) | 2012-10-17 | 2013-10-16 | グルコース取り込みを改善するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9346835B2 (https=) |
| EP (1) | EP2909216B1 (https=) |
| JP (1) | JP6377620B2 (https=) |
| CA (1) | CA2887679C (https=) |
| ES (1) | ES2618374T3 (https=) |
| WO (1) | WO2014062794A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2618374T3 (es) | 2012-10-17 | 2017-06-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Composiciones y métodos para mejorar la absorción de glucosa |
| US10047107B2 (en) | 2014-04-23 | 2018-08-14 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Small molecule analogs of E4orf1 |
| AU2017324510B2 (en) | 2016-09-07 | 2023-08-31 | Temple University - Of The Commonwealth System Of Higher Education | Compositions and methods for treatment of insulin resistance |
| WO2021026495A1 (en) | 2019-08-07 | 2021-02-11 | Texas Tech University System | Ad36e40rf1: a therapeutic treatment for alzheimer's disease |
| TW202206062A (zh) | 2020-04-24 | 2022-02-16 | 美國坦普大學 高等教育聯邦系統 | 治療非酒精性脂肪肝炎的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858592B2 (en) * | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
| CA2632013C (en) | 2005-11-30 | 2013-02-26 | Wayne State University | Adenovirus 36 e4 orf 1 gene and protein and their uses |
| JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| US8951980B2 (en) | 2010-07-08 | 2015-02-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Adenovirus Ad36 E4 orf1 protein for prevention and treatment of non-alcoholic fatty liver disease |
| WO2012112670A1 (en) * | 2011-02-16 | 2012-08-23 | Albert Einstein College Of Medicine Of Yeshiva University | Novel lipogenic inhibitors and uses thereof |
| ES2618374T3 (es) * | 2012-10-17 | 2017-06-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Composiciones y métodos para mejorar la absorción de glucosa |
-
2013
- 2013-10-16 ES ES13783206.9T patent/ES2618374T3/es active Active
- 2013-10-16 JP JP2015537790A patent/JP6377620B2/ja active Active
- 2013-10-16 EP EP13783206.9A patent/EP2909216B1/en active Active
- 2013-10-16 US US14/434,276 patent/US9346835B2/en active Active
- 2013-10-16 CA CA2887679A patent/CA2887679C/en active Active
- 2013-10-16 WO PCT/US2013/065227 patent/WO2014062794A1/en not_active Ceased
-
2016
- 2016-01-07 US US14/990,236 patent/US9469659B2/en active Active
- 2016-05-23 US US15/161,591 patent/US9714259B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536324A5 (https=) | ||
| JP2013047277A5 (https=) | ||
| JP2017538773A5 (https=) | ||
| JP2016506960A5 (https=) | ||
| JP2017505785A5 (https=) | ||
| JP2014507477A5 (https=) | ||
| JP2015520140A5 (https=) | ||
| JP2019516713A5 (https=) | ||
| JP2013014622A5 (https=) | ||
| JP2011105738A5 (https=) | ||
| JP2016506962A5 (https=) | ||
| JP2018507914A5 (https=) | ||
| JP2014521688A5 (https=) | ||
| JP2016503793A5 (https=) | ||
| JP2016505614A5 (https=) | ||
| JP2017526677A5 (https=) | ||
| JP2013522326A5 (https=) | ||
| HK1214968A1 (zh) | 用於非酒精性脂肪肝病(nafld)的新组合物 | |
| JP2013542261A5 (https=) | ||
| MX373153B (es) | Derivados de diazacarbazol como ligandos de tau para tomografía por emisión de positrones (pet). | |
| JP2013532130A5 (https=) | ||
| JP2017533263A5 (https=) | ||
| JP2017531013A5 (https=) | ||
| MX337396B (es) | Metodo para el tratamiento de enfermedades del riñon poliquisticas con derivados de ceramica. | |
| MX2016006576A (es) | Composiciones nutritivas con fosfolipidos. |